• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-X filed by Bright Minds Biosciences Inc.

    12/23/25 5:27:05 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRUG alert in real time by email
    F-X 1 drug20251222_fx.htm FORM F-X drug20251222_fx.htm

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM F-X

     

    APPOINTMENT OF AGENT FOR SERVICE OF PROCESS
    AND UNDERTAKING

     

     

    A.

    Name of issuer or person filing (“Filer”): Bright Minds Biosciences Inc.

     

    B.

    (1)     This is [check one]:

     

     

    ☒

    an original filing for the Filer.

     

     

    ☐

    an amended filing for the Filer.

     

     

    (2)

    Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rule 101(b)(9)  ☐

     

     

    (3)

    A filer may also file the Form F-X in paper under a hardship exemption provided by Regulation S-T Rule 201 or 202 (17 CFR 232.201 or 232.202). When submitting the Form F-X in paper under a hardship exemption, a filer must provide the legend required by Regulation S-T Rule 201(a)(2) or 202(c) (17 CFR 232.201(a)(2) or 232.202(c)) on the cover page of the Form F-X.

     

    C.

    Identify the filing in conjunction with which this Form is being filed:

     

    Name of registrant: Bright Minds Biosciences Inc.
       
    Form type: Form 40-F
       
    File Number (if known):  001-40997
       
    Filed by:  Bright Minds Biosciences Inc.
       
    Date Filed (if filed concurrently, so indicate):   Concurrently

     

     

    D.

    The Filer is incorporated or organized under the laws of British Columbia, Canada, and has its principal place of business at:

     

     

    400 N Aberdeen St Suite 900

    Chicago, IL 60642

    (U.S. Corporate headquarters)

    1122 Mainland St #228

    Vancouver, BC Canada V6B 5L1

    (Canadian Corporate headquarters)

     

    Telephone: (647) 407-2515

    (Address and telephone number of Registrant’s principal executive office)

     

     

     

     

    E.

    The Filer designates and appoints:

     

    C T Corporation System
    (the “Agent”)

    28 Liberty Street, New York, NY 10005

    Telephone: (212) 894-8940

     

    as the agent of the Filer upon whom may be served any process, pleadings, subpoenas, or other papers in:

     

     

    (a)

    any investigation or administrative proceeding conducted by the Commission; and

     

     

    (b)

    any civil suit or action brought against the Filer or to which the Filer has been joined as defendant or respondent, in any appropriate court in any place subject to the jurisdiction of any state or of the United States or of any of its territories or possessions or of the District of Columbia, where the investigation, proceeding or cause of action arises out of or relates to or concerns (i) any offering made or purported to be made in connection with the securities registered or qualified by the Filer on Form F-3 on August 26, 2025, or any purchases or sales of any security in connection therewith; (ii) the securities in relation to which the obligation to file an annual report on Form 40-F arises, or any purchases or sales of such securities; (iii) any tender offer for the securities of a Canadian issuer with respect to which filings are made by the Filer with the Commission on Schedule 13E-4F, 14D-1F or 14D-9F; or (iv) the securities relation to which the Filer acts as trustee pursuant to an exemption under Rule 10a-5 under the Trust Indenture Act of 1939. The Filer stipulates and agrees that any such civil suit or action or administrative proceeding may be commenced by the service of process upon, and that service of an administrative subpoena shall be effected by service upon such agent for service of process, and that service as aforesaid shall be taken and held in all courts and administrative tribunals to be valid and binding as if personal service thereof had been made.

     

    F.

    Each person filing this Form in connection with:

     

     

    (a)

    the use of Form F-10, 40-F or Schedule 13E-4F, 14D-1F or 14D-9F stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date the issuer of the securities to which such Forms and Schedules relate has ceased reporting under the Exchange Act;

     

     

    (b)

    the use of Form F-8, Form F-80 or Form CB stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed following the effective date of the latest amendment to such Form F-8, Form F-80 or Form CB;

     

     

    (c)

    its status as trustee with respect to securities registered on Form F-7, F-8, F-10 or F-80 stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time during which any of the securities subject to the indenture remain outstanding; and

     

     

    (d)

    the use of Form 1-A or other Commission form for an offering pursuant to Regulation A stipulates and agrees to appoint a successor agent for service of process and file an amended Form F-X if the Filer discharges the Agent or the Agent is unwilling or unable to accept service on behalf of the Filer at any time until six years have elapsed from the date of the last sale of securities in reliance upon the Regulation A exemption.

     

    Each filer further undertakes to advise the Commission promptly of any change to the Agent’s name or address during the applicable period by amendment of this Form, referencing the file number of the relevant form in conjunction with which the amendment is being filed.

     

    G.

    Each person filing this Form, other than a trustee filing in accordance with General Instruction I. (a) of this Form, undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to: the Forms, Schedules and offering statements described in General Instructions I. (a), I. (b), I. (c), I. (d) and I. (f) of this Form, as applicable; the securities to which such Forms, Schedules and offering statements relate; and the transactions in such securities.

     

     

     

     

    The Filer certifies that it has duly caused this power of attorney, consent, stipulation and agreement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vancouver, Country of Canada, this 23rd day of December, 2025.

     

     

    BRIGHT MINDS BIOSCIENCES INC.

     

     

     

     

     

     

     

     

     

     

    By:

    /s/ Ryan Cheung

     

     

    Name:

    Ryan Cheung

     

     

    Title:

    Chief Financial Officer

     

     

    This statement has been signed by the following persons in the capacities and on the date indicated.

     

     

    C T CORPORATION SYSTEM

    (as Agent for Service of Process)

     

     

     

     

     

     

    By:

    /s/ Devin Randolph

     

     

    Name:

    Devin Randolph

     

     

    Title:

    Assistant Secretary

     

      Date: December 23, 2025  

     

     
    Get the next $DRUG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRUG

    DatePrice TargetRatingAnalyst
    4/13/2026$145.00Buy
    Jefferies
    9/8/2025$72.00Buy
    BTIG Research
    5/13/2025Buy
    TD Cowen
    5/7/2025$80.00Buy
    Chardan Capital Markets
    1/23/2025$93.00Overweight
    Piper Sandler
    1/10/2025Overweight
    Cantor Fitzgerald
    1/10/2025$85.00Buy
    H.C. Wainwright
    11/26/2024$75.00Outperform
    Robert W. Baird
    More analyst ratings

    $DRUG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Bright Minds Biosciences with a new price target

    Jefferies initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $145.00

    4/13/26 8:51:07 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Bright Minds Biosciences with a new price target

    BTIG Research initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $72.00

    9/8/25 8:48:58 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Bright Minds Biosciences

    TD Cowen initiated coverage of Bright Minds Biosciences with a rating of Buy

    5/13/25 9:38:46 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRUG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bright Minds Biosciences to Present at Upcoming Conferences

    NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:TD Cowen 46th Annual Health Care ConferenceDATE:Wednesday, March 4, 2026TIME:9:10am ETWEBCAST:https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/cy8oQuZ2XnJiLiEqXopBn7 EVENT: Leerink Partners 2026 Global Healthcare ConferenceDATE: Monday, March 9, 2026WEBCAST:No

    2/25/26 4:30:00 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the "Offering"). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds. The Company intends to use the net proceeds

    1/9/26 11:56:05 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

    NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the "Offering"). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities being sold in this Offering are being offered by Bright Minds. The closing

    1/7/26 9:33:26 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRUG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

    4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

    11/6/24 4:20:48 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

    4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

    10/17/24 5:11:29 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Cormorant Asset Management, Lp claimed ownership of 452,409 shares (SEC Form 3)

    3 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

    10/17/24 5:07:59 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRUG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.

    SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

    2/17/26 4:33:03 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.

    SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

    2/17/26 4:00:02 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Bright Minds Biosciences Inc.

    6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

    2/13/26 6:04:46 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRUG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

    4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

    11/6/24 4:20:48 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

    4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

    10/17/24 5:11:29 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRUG
    Leadership Updates

    Live Leadership Updates

    View All

    Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

    -- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an

    1/7/25 6:50:00 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

    -- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a

    2/27/23 6:50:00 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Minds Biosciences Announces Resignation of Board Member

    VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board. "In his short tenure on the Board, Doug's scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging br

    1/9/23 4:05:00 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRUG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bright Minds Biosciences Inc.

    SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

    11/12/24 4:15:24 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bright Minds Biosciences Inc.

    SC 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

    11/6/24 4:06:00 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Bright Minds Biosciences Inc.

    SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

    11/5/24 3:25:38 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRUG
    Financials

    Live finance-specific insights

    View All

    Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

    BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no change in total sleep durationCompany has initiated preparations for global registrational trials in both DEE and Absence Seizure patientsBright Minds to hold conference call and live webcast at 8AM ET today NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical

    1/6/26 7:16:55 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

    – Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. Webcast Information The Bright Minds virtual event will be webcast live and a replay will be available after th

    1/5/26 4:30:00 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

    -- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape.

    4/19/22 6:50:00 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care